{"pmid":32208485,"title":"COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","text":["COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?","JAMA","Patel, Ankit B","Verma, Ashish","32208485"],"journal":"JAMA","authors":["Patel, Ankit B","Verma, Ashish"],"date":"2020-03-26T11:00:00Z","year":2020,"_id":"32208485","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4812","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1662254179969662976,"score":7.055025,"similar":[{"pmid":32186711,"title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","text":["Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.","J Travel Med","Diaz, James H","32186711"],"abstract":["Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections."],"journal":"J Travel Med","authors":["Diaz, James H"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186711","week":"202012|Mar 16 - Mar 22","doi":"10.1093/jtm/taaa041","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1661633092426661889,"score":154.07379},{"pmid":32129518,"title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","text":["Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.","Drug Dev Res","Gurwitz, David","32129518"],"abstract":["At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility."],"journal":"Drug Dev Res","authors":["Gurwitz, David"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129518","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ddr.21656","keywords":["AT1R blockers","COVID-19 epidemic","SARS-CoV-2","angiotensin-converting enzyme 2 (ACE2)","losartan"],"source":"PubMed","locations":["losartan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661359647676694528,"score":107.31018},{"pmid":32125455,"title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.","text":["Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.","Intensive Care Med","Zhang, Haibo","Penninger, Josef M","Li, Yimin","Zhong, Nanshan","Slutsky, Arthur S","32125455"],"journal":"Intensive Care Med","authors":["Zhang, Haibo","Penninger, Josef M","Li, Yimin","Zhong, Nanshan","Slutsky, Arthur S"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125455","week":"202010|Mar 02 - Mar 08","doi":"10.1007/s00134-020-05985-9","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1661359647634751490,"score":99.52001},{"pmid":32199943,"title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.","text":["Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.","SARS-CoV-2, the newly identified human coronavirus causing severe pneumonia epidemic, was probably originated from Chinese horseshoe bats. However, direct transmission of the virus from bats to humans is unlikely due to lack of direct contact, implying the existence of unknown intermediate hosts. Angiotensin converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, but only ACE2s of certain species can be utilized by SARS-CoV-2. Here, we evaluated and ranked the receptor-utilizing capability of ACE2s from various species by phylogenetic clustering and sequence alignment with the currently known ACE2s utilized by SARS-CoV-2. As a result, we predicted that SARS-CoV-2 tends to utilize ACE2s of various mammals, except murines, and some birds, such as pigeon. This prediction may help to screen the intermediate hosts of SARS-CoV-2.","Microbes Infect","Qiu, Ye","Zhao, Yuan-Bo","Wang, Qiong","Li, Jin-Yan","Zhou, Zhi-Jian","Liao, Ce-Heng","Ge, Xing-Yi","32199943"],"abstract":["SARS-CoV-2, the newly identified human coronavirus causing severe pneumonia epidemic, was probably originated from Chinese horseshoe bats. However, direct transmission of the virus from bats to humans is unlikely due to lack of direct contact, implying the existence of unknown intermediate hosts. Angiotensin converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, but only ACE2s of certain species can be utilized by SARS-CoV-2. Here, we evaluated and ranked the receptor-utilizing capability of ACE2s from various species by phylogenetic clustering and sequence alignment with the currently known ACE2s utilized by SARS-CoV-2. As a result, we predicted that SARS-CoV-2 tends to utilize ACE2s of various mammals, except murines, and some birds, such as pigeon. This prediction may help to screen the intermediate hosts of SARS-CoV-2."],"journal":"Microbes Infect","authors":["Qiu, Ye","Zhao, Yuan-Bo","Wang, Qiong","Li, Jin-Yan","Zhou, Zhi-Jian","Liao, Ce-Heng","Ge, Xing-Yi"],"date":"2020-03-23T11:00:00Z","year":2020,"_id":"32199943","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.micinf.2020.03.003","keywords":["SARS-CoV-2","angiotensin converting enzyme 2 (ACE2)","coronavirus","phylogenetic analysis","receptor utilization"],"source":"PubMed","locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1661985684336934912,"score":97.57118},{"pmid":32166940,"title":"[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].","text":["[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].","Zhonghua Xin Xue Guan Bing Za Zhi","Shi, H Z","Ma, P","Gao, F Y","Chen, G L","Yu, Y H","Wang, X D","Xian, E D","Dong, Erdan","32166940"],"journal":"Zhonghua Xin Xue Guan Bing Za Zhi","authors":["Shi, H Z","Ma, P","Gao, F Y","Chen, G L","Yu, Y H","Wang, X D","Xian, E D","Dong, Erdan"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32166940","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn112148-20200308-00171","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647944081408,"score":88.77643}]}